Last $93.67 USD
Change Today -1.23 / -1.30%
Volume 947.9K
QCOR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

questcor pharmaceuticals (QCOR) Key Developments

Questcor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Questcor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total net sales were $278,830,000 against $184,573,000 a year ago. Income from operations was $147,764,000 against $103,072,000 a year ago. Income before income taxes was $147,598,000 against $103,092,000 a year ago. Net income was $96,436,000 against $69,123,000 a year ago. Diluted income per share was $1.54 against $1.12 a year ago. Adjusted net income was $115,822,000 against $83,323,000 a year ago. Adjusted net income per diluted share was $1.85 against $1.35 a year ago. Adjusted consolidated net sales $278,830,000 against $196,073,000 a year ago. Cash flow from operations was $99 million compared to $82 million a year ago. For the six months, Total net sales were $505,934,000 against $319,702,000 a year ago. Income from operations was $261,627,000 against $161,419,000 a year ago. Income before income taxes was $260,515,000 against $160,609,000 a year ago. Net income was $170,746,000 against $108,185,000 a year ago. Diluted income per share was $2.75 against $1.79 a year ago. Adjusted net income was $202,083,000 against $128,987,000 a year ago. Adjusted net income per diluted share was $3.25 against $2.13 a year ago. Adjusted consolidated net sales $505,934,000 against $331,202,000 a year ago. Net cash flows provided by operating activities was $205,431,000 against $122,991,000 a year ago. Purchase of property and equipment was $8,266,000 against $1,138,000 a year ago.

Questcor Pharmaceuticals, Inc.(NasdaqGS:QCOR) added to Russell 1000 Index

Questcor Pharmaceuticals, Inc. will be added to the Russell 1000 Index.

Questcor Pharmaceuticals, Inc.(NasdaqGS:QCOR) dropped from Russell 2000 Index

Questcor Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

Questcor Pharmaceuticals Enters into Collaboration Agreement for Melanocortin Therapeutics

Questcor Pharmaceuticals, Inc. has entered into a development collaboration agreement with a European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. The agreement includes a technology platform that provides Questcor with a novel library of melanocortin peptides. The company has already conducted initial preclinical evaluation on a number of peptides and from this exercise has selected lead peptides with which to move forward. Unlike Acthar and Synacthen, which are broad-acting melanocortin peptide formulations which bind to all five known melanocortin receptors, the licensed technology platform provides peptides designed to target specific melanocortin receptors that Questcor believes are particularly relevant to autoimmune and inflammatory diseases. Among other key characteristics, the peptides have been designed to minimize activation of the melanocortin 2 receptor in order to limit endogenous cortisol production and related steroid side effects. The company believes this technology platform has extensive and long term intellectual property protection. The company will initially focus on conducting formulation and manufacturing activities involving the lead peptides and performing additional preclinical research in order to match the lead peptides with lead indications for clinical development. Under the terms of the collaboration, Questcor has secured an exclusive worldwide license to the peptides and technology. Questcor will fund the development of the peptides and will have the option to acquire the technology at a later date.

Questcor Pharmaceuticals, Inc. Declares Quarterly Dividend, Payable on July 8, 2014

Questcor Pharmaceuticals, Inc. announced a quarterly dividend, which is scheduled on July 8, 2014. Stockholders of record on July 1, 2014, will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 1.38%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QCOR:US $93.67 USD -1.23

QCOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.97 USD -0.14
CR Bard Inc $153.13 USD +4.28
Novartis AG SFr.79.40 CHF -0.55
Sanofi €76.33 EUR +0.35
View Industry Companies
 

Industry Analysis

QCOR

Industry Average

Valuation QCOR Industry Range
Price/Earnings 16.6x
Price/Sales 5.7x
Price/Book 10.0x
Price/Cash Flow 16.1x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUESTCOR PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.